Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction.

ABSTRACT:

Background

Recently, two molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) have been proposed: the "Classical" and "Basal-like" subtypes, with the former showing better clinical outcomes than the latter. However, the "molecular" classification has not been applied in real-world clinical practice. This study aimed to establish patient-derived organoids (PDOs) for PDAC and evaluate their application in subtype classification and clinical outcome prediction.

Methods

We utilized tumor samples acquired through endoscopic ultrasound-guided fine-needle biopsy and established a PDO library for subsequent use in morphological assessments, RNA-seq analyses, and in vitro drug response assays. We also conducted a prospective clinical study to evaluate whether analysis using

SUBMITTER: Matsumoto K 

PROVIDER: S-EPMC11217054 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature